Coronavirus Update: Pfizer CEO Thinks Vaccine Price Rise Likely Post-Pandemic
Plus: SinoVac Results Disappoint, AstraZeneca Files in EU
Executive Summary
Companies will raise their COVID-19 vaccine prices once the pandemic is over – but key long-term data will determine which comes out on top.
You may also be interested in...
J.P. Morgan Day 1: Companies Make Deal-Making, COVID-19 Promises
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Business development is key topic for Amgen and Vertex; BioNTech talks COVID-19 vaccine supply while Merck KGAA's new CEO pledges to rise to meet the challenges posed by COVID-19.
UK Begins Controversial 12 Week Strategy With AZ and Pfizer Vaccines
Entering a new lockdown, the UK sees its plans to space out doses of the COVID-19 vaccines to 12 weeks as crucial to overcoming the pandemic.
China Grants Conditional Approval To CNBG COVID Vaccine
State-owned China National Biotec Group becomes the first to get the greenlight for its inactivated virus-based vaccine to prevent COVID-19.